Seres Therapeutics Inc
NASDAQ:MCRB

Watchlist Manager
Seres Therapeutics Inc Logo
Seres Therapeutics Inc
NASDAQ:MCRB
Watchlist
Price: 0.9905 USD 8.19% Market Closed
Market Cap: 169.1m USD
Have any thoughts about
Seres Therapeutics Inc?
Write Note

Seres Therapeutics Inc
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Seres Therapeutics Inc
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
Seres Therapeutics Inc
NASDAQ:MCRB
Total Equity
$23.9m
CAGR 3-Years
-49%
CAGR 5-Years
N/A
CAGR 10-Years
21%
Abbvie Inc
NYSE:ABBV
Total Equity
$6B
CAGR 3-Years
-24%
CAGR 5-Years
N/A
CAGR 10-Years
3%
Gilead Sciences Inc
NASDAQ:GILD
Total Equity
$18.4B
CAGR 3-Years
-5%
CAGR 5-Years
-2%
CAGR 10-Years
3%
Amgen Inc
NASDAQ:AMGN
Total Equity
$7.5B
CAGR 3-Years
-3%
CAGR 5-Years
-7%
CAGR 10-Years
-11%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Total Equity
$15.6B
CAGR 3-Years
18%
CAGR 5-Years
24%
CAGR 10-Years
30%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Total Equity
$29.3B
CAGR 3-Years
19%
CAGR 5-Years
23%
CAGR 10-Years
28%
No Stocks Found

Seres Therapeutics Inc
Glance View

Market Cap
168.6m USD
Industry
Biotechnology

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. The company is headquartered in Cambridge, Massachusetts and currently employs 333 full-time employees. The company went IPO on 2015-06-26. The firm is engaged in developing a class of biological drugs, which are designed to treat disease by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The firm's lead product candidate, SER-109, is designed to reduce further recurrences of Clostridioides difficle infection (CDI). The company is also developing therapeutics, such as SER-155, to specifically target infections and antimicrobial resistance. SER-155, a microbiome therapeutic candidate consisting of a consortium of cultivated bacteria, is designed to reduce incidences of gastrointestinal infections, bloodstream infections and graft versus host disease (GvHD) in patients receiving allogeneic hematopoietic stem cell transplantation (allo-HSCT). In addition, using its microbiome therapeutics platform, the Company is developing SER-287 and SER-301 to treat ulcerative colitis (UC).

MCRB Intrinsic Value
0.5699 USD
Overvaluation 42%
Intrinsic Value
Price

See Also

What is Seres Therapeutics Inc's Total Equity?
Total Equity
23.9m USD

Based on the financial report for Sep 30, 2024, Seres Therapeutics Inc's Total Equity amounts to 23.9m USD.

What is Seres Therapeutics Inc's Total Equity growth rate?
Total Equity CAGR 10Y
21%

The average annual Total Equity growth rates for Seres Therapeutics Inc have been -49% over the past three years , and 21% over the past ten years .

Back to Top